公开(公告)号：US20130302360A1

公开(公告)日：2013-11-14

申请号：US13876439

申请日：2011-09-27

申请人： Ken-ichi Asai ,  Kazuo Kawakami ,  Masami Mochizuki

发明人： Ken-ichi Asai ,  Kazuo Kawakami ,  Masami Mochizuki

IPC分类号： A61K39/39

CPC分类号： A61K39/39 ,  A61K38/162 ,  A61K39/099 ,  A61K39/12 ,  A61K2039/52 ,  A61K2039/5252 ,  A61K2039/541 ,  A61K2039/543 ,  A61K2039/55594 ,  C07K14/235 ,  C12N2710/10034 ,  C12N2760/18034

摘要： Problem to be Solved: The present invention provides a novel mucosal adjuvant.Solution: The present invention provides a mucosal adjuvant composition containing at least a composition comprising molecules having a molecular weight in a range of 100 to 300 kDa obtained from cells or culture fluid of Bordetella bronchiseptica. Administration of the mucosal adjuvant composition to a non-human animal at a surface of the mucous membrane can enhance immunity at the surface of mucous membrane. Therefore preventive effects against trans-mucosal infection can be increased by administering an inactivated vaccine against trans-mucosal infection and the mucosal adjuvant composition to a non-human animal at a surface of mucous membrane. The present invention is effective for preventing trans-mucosal infections, including one or more infections of e.g., canine parainfluenza, canine adenovirus, canine coronavirus, canine parvovirus, canine distemper virus, canine herpesvirus, reovirus and pneumovirus.

摘要翻译： 待解决的问题：本发明提供一种新型粘膜佐剂。 解决方案：本发明提供一种粘膜佐剂组合物，其至少含有由支气管炎博德特氏菌的细胞或培养液获得的分子量为100-300kDa的分子的组合物。 在粘膜表面向非人动物施用粘膜佐剂组合物可增强粘膜表面的免疫力。 因此，可以通过在粘膜表面施用针对反粘膜感染的灭活疫苗和粘膜佐剂组合物至非人动物来增加对反粘膜感染的预防效果。 本发明对于预防反粘膜感染，包括一种或多种例如副流感病毒，犬腺病毒，犬冠状病毒，犬细小病毒，犬瘟热病毒，犬疱疹病毒，呼肠孤病毒和肺病毒感染是有效的。

公开(公告)号：US09381241B2

公开(公告)日：2016-07-05

申请号：US13876439

申请日：2011-09-27

申请人： Ken-ichi Asai ,  Kazuo Kawakami ,  Masami Mochizuki

发明人： Ken-ichi Asai ,  Kazuo Kawakami ,  Masami Mochizuki

IPC分类号： A61K39/00 ,  A61K39/39 ,  A61K38/16 ,  C07K14/235 ,  A61K39/12 ,  A61K39/02

CPC分类号： A61K39/39 ,  A61K38/162 ,  A61K39/099 ,  A61K39/12 ,  A61K2039/52 ,  A61K2039/5252 ,  A61K2039/541 ,  A61K2039/543 ,  A61K2039/55594 ,  C07K14/235 ,  C12N2710/10034 ,  C12N2760/18034

摘要： Problem to be Solved: The present invention provides a novel mucosal adjuvant.Solution: The present invention provides a mucosal adjuvant composition containing at least a composition comprising molecules having a molecular weight in a range of 100 to 300 kDa obtained from cells or culture fluid of Bordetella bronchiseptica. Administration of the mucosal adjuvant composition to a non-human animal at a surface of the mucous membrane can enhance immunity at the surface of mucous membrane. Therefore preventive effects against trans-mucosal infection can be increased by administering an inactivated vaccine against trans-mucosal infection and the mucosal adjuvant composition to a non-human animal at a surface of mucous membrane. The present invention is effective for preventing trans-mucosal infections, including one or more infections of e.g., canine parainfluenza, canine adenovirus, canine coronavirus, canine parvovirus, canine distemper virus, canine herpesvirus, reovirus and pneumovirus.

摘要翻译： 待解决的问题：本发明提供一种新型粘膜佐剂。 解决方案：本发明提供一种粘膜佐剂组合物，其至少含有由支气管炎博德特氏菌的细胞或培养液获得的分子量为100-300kDa的分子的组合物。 在粘膜表面向非人动物施用粘膜佐剂组合物可提高粘膜表面的免疫力。 因此，可以通过在粘膜表面施用针对反粘膜感染的灭活疫苗和粘膜佐剂组合物至非人动物来增加对反粘膜感染的预防效果。 本发明对于预防反粘膜感染，包括一种或多种例如副流感病毒，犬腺病毒，犬冠状病毒，犬细小病毒，犬瘟热病毒，犬疱疹病毒，呼肠孤病毒和肺病毒感染是有效的。